publication date: Jul. 10, 2015

House Passes 21st Century Cures Act

The U.S. House of Representatives July 10 passed H.R. 6, The 21st Century Cures Act without amendments by a 344 to 77 vote.

The bill—designed to modernize clinical trials and streamline the drug approval process—would boost NIH funding by $1.75 billion in mandatory funding a year over the next five years, for a total of $8.75 billion, and FDA’s budget by a total of $550 million.

The bill was put together by House Energy and Commerce Committee Chairman Fred Upton (R-Mich.), Oversight and Investigations Subcommittee Ranking Member Diana DeGette (D-Colo.), Health Subcommittee Chairman Joe Pitts (R-Penn.), full committee Ranking Member Frank Pallone, Jr., (D-N.J.), and Health Subcommittee Ranking Member Gene Green (D-Texas).

“Today, we took a big leap on the path to cures, but we still have much work left to do. The 344 votes today should be a springboard for action,” the bill’s sponsors said in a statement. “On to the Senate.”

The bill advances initiatives in big data and precision medicine, said American Society of Clinical Oncology President Julie Vose.

“Big data and precision medicine have enormous potential to improve the way we treat cancer. ASCO currently has two major initiatives underway in this arena with CancerLinQ, a big data project aimed to rapidly improve the overall quality of cancer care, and the Targeted Agent and Profiling Utilization Registry Study, our first-ever clinical trial, designed to learn from the … Continue reading 41-27 House Passes 21st Century Cures Act

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.